Shares of Nuformix plc (LON:NFX – Get Free Report) shot up 4.4% on Friday . The company traded as high as GBX 0.14 and last traded at GBX 0.14. 20,339,689 shares were traded during mid-day trading, a decline of 32% from the average daily volume of 29,953,295 shares. The stock had previously closed at GBX 0.14.
Nuformix Price Performance
The firm has a market capitalization of £3.68 million, a P/E ratio of -4.81 and a beta of 1.52. The firm has a 50-day moving average price of GBX 0.17 and a two-hundred day moving average price of GBX 0.19.
Nuformix (LON:NFX – Get Free Report) last issued its earnings results on Thursday, May 28th. The company reported GBX (0.02) earnings per share (EPS) for the quarter.
About Nuformix
Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis. It also has an option agreement with Oxilio Ltd. for NXP001 for oncology indications.
Further Reading
- Five stocks we like better than Nuformix
- Is Best Buy the AI Winner Hiding in the Electronics Aisle?
- Applied Materials Beat Everything but Wall Street’s Expectations for Margins
- Back From Orbit, Intuitive Machines’ Share Price Enters the Buy Zone
- Texas Roadhouse and Brinker International Have the Recipe Rivals Are Missing
Receive News & Ratings for Nuformix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuformix and related companies with MarketBeat.com's FREE daily email newsletter.
